

# Prevention with Synbiosis and Treatment with Thalidomide and Celecoxib for Amyotrophic Lateral Sclerosis

Masato Hada<sup>1</sup>, Muhammad Akram<sup>2</sup>

<sup>1</sup>Hada Clinic, Sophia Hada, Japan

<sup>2</sup>Department of Eastern Medicine, Government College University, Faisalabad, Pakistan

## Email address:

clinichada@cy.tnc.ne.jp (Masato Hada), makram\_0451@hotmail.com (Muhammad Akram)

## To cite this article:

Masato Hada, Muhammad Akram. Prevention with Synbiosis and Treatment with Thalidomide and Celecoxib for Amyotrophic Lateral Sclerosis. *American Journal of Biomedical and Life Sciences*. Vol. 10, No. 5, 2022, pp. 146-154. doi: 10.11648/j.ajbls.20221005.13

**Received:** August 3, 2022; **Accepted:** October 21, 2022; **Published:** October 28, 2022

**Abstract:** There are a variety of types of amyotrophic lateral sclerosis (ALS). Most patients with ALS (90%) are classified into the sporadic type (SALS) without heredity. 5% of SALS and 3% of familial type (FALS) are caused by mutations in the 43-kDa trans-activating response region DNA-binding protein (TDP-43). 20% of FALS are caused by the mutation of Cu, Zn superoxide dismutase (SOD1). Superoxide dismutases (SODs) catalyze the dismutation which reaction breaks down harmful radicals into non-reactive molecules in the cells. Mutated SOD1 leads to the production of ROS that causes neuronal death. Recently, a number of new causal factors have been found to link to the pathogenesis of ALS. Characteristic pathological mechanism of ALS is the function of cytosolic protein aggregates. Normal cell functions are disturbed in the cytosol and lead to abnormal cellular processes such as oxidative stress, excitotoxicity, mitochondrial dysfunction. Matrix metalloproteinases (MMPs) and Tissue inhibitors of metalloproteinases (TIMPs) process physiological tissue remodeling and pathological conditions, both of which include vascular and fibrotic regenerations, angiogenesis and destructive diseases such as ALS and cancers. The Receptor for Advanced Glycation End Products (RAGE) plays an important role in ALS causing inflammation oxidative stress and cellular dysfunction. RAGE is also expressed in neurons, vascular cells, microglia, and astrocytes in the central nervous system (CNS).  $\beta$ -N-methylamino-L-alanine (BMAA) is a potential environmental factor in ALS, which is derived from the cycad plant synthesized by cyanobacteria. BMAA is consumed mainly as cycad flour. Dysfunction of these factors are closely associated with nuclear factor- $\kappa$ B (NF- $\kappa$ B) and activator protein-1 (AP-1). The drugs that suppress activated NF- $\kappa$ B are currently thalidomide, celecoxib and valproic acid. These drugs might slow down the exacerbation of ALS as they are effective for cancers.

**Keywords:** Amyotrophic Lateral Sclerosis, Thalidomide, Celecoxib, Valproic Acid, Probiotics

## 1. Introduction

### 1.1. Metalloproteinases and Superoxide Dismutase

Superoxide dismutases (SODs) are metalloenzymes consistent of Cu, Zn-SOD, Fe-SOD, Mn-SOD and Ni-SOD found in all living cells. SODs catalyze the dismutation in which the reaction between two identical molecules  $O_2^-$  into molecular oxygen and hydrogen peroxide ( $H_2O_2$ ). This reaction breaks down harmful radicals into non-reactive molecules in the cells [1]. 90% cases of ALS are sporadic and without family history, 10% cases are familial and autosomal dominant. Moreover, approximately 20% of familial cases are related to mutated superoxide dismutase 1 (SOD1) gene [2, 3].

Astrocytes and microglia with mutant SOD1 express a variety of pro-inflammatory cytokines through NF- $\kappa$ B, resulting neuroinflammation and motor neuron death in ALS [2, 4].

Endopeptidases are proteolytic hydrolases that catalyze peptide bonds of nonterminal amino acids. Metalloproteinases (MPs) are zinc dependent endopeptidases and degrade a variety of proteins such as collagen and elastin in extracellular matrix (ECM) [5].

MPs play potent roles between cells and ECM leading cell differentiation, proliferation and survival. Tissue remodeling is defined as tissue reorganization that are important for tissue regeneration, wound healing, organ development such as muscle and nerves [6, 7]. Matrix metalloproteinases (MMPs) are zinc containing multidomain metalloproteinases and play

an important role in tissue remodeling and degradation of ECM [8]. MMPs were initially classified on substrate specificity into five groups: collagenases, gelatinases, stromelysins, matrilysins, and membrane type [9]. MMP family consists of more than 20 members and 14 are in the vasculature [10].

MMPs process physiological tissue remodeling and pathological conditions, both of which include vascular and fibrotic regenerations, angiogenesis and destructive diseases such as ALS and cancers [11].

Neuromuscular degeneration of ALS is associated with many molecules, especially MMPs and tissue inhibitors of metalloproteinases (TIMPs) play an important role in pathogenesis. MMPs, secreted by many cells including fibroblasts, vascular smooth muscle and leukocytes, act as pericellular proteolysis [12]. It is important to adopt probiotics for oxidative stress, and chemotherapeutic agents that incorporate molecular pathways to NF- $\kappa$ B and, moreover growth factors.

TIMPs are specific and endogenous inhibitors of MMPs that control the function of MMPs in the tissues [13, 14]. In pathophysiological conditions, MMP-9 contributes to the development and wound healing, and also contribute to the immune response that exacerbate disease progression such as immunological diseases and cancers [15]. MMPs such as MMP-1, 2, 3, and 9 play an important role in the progression of ALS, especially MMP-9 might cause neuromuscular degeneration [16]. MMP-9 has the ability to degrade gelatinase B, therefore, is classified in the gelatinase subgroup 9. MMP-2 and MMP -9 belong to gelatinases group and readily degrade degenerated collagens and gelatins. MMP-9 plays a major role in tissue remodeling such as embryo implantation, neovascularization and immune cell function. MMP-9 expression is closely associated with NF- $\kappa$ B and AP-1 [17].

TIMPs are widely distributed in humans, and specific and endogenous inhibitors of MMPs that control the function of MMPs in the tissues.

TIMPs consist of four TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) and inhibit MMPs binding under stoichiometric amount 1:1. The imbalance between MMPs and TIMPs affect the level of MMP activity and derive pathological function of MMPs [13 14].

The drugs that suppress activated NF- $\kappa$ B are currently thalidomide, celecoxib and valproic acid. These drugs might slow down the exacerbation of ALS as they are effective for cancers.

### **1.2. Receptor for Advanced Glycation End Products (RAGE) and ALS**

Age-related dysbiosis are well known and promote inflammation by oxidative stress due to imbalance of GI tract [18]. Skeletal muscle, adipose tissue and the liver are three major targets of insulin because these tissues have overexpressed insulin receptors can deposit and store glucose [19]. About 75% of insulin-dependent postprandial glucose is disposed in the skeletal muscle [20]. Advanced glycation end-products (AGEs) are produced from glucose and proteins with non-enzymic activity in a variety of tissues during aging. AGEs store in various systemic tissues under chronic

hyperglycemic circumstances and cause vascular disorders like diabetic vascular complication [21].

Currently dynapenia and sarcopenia are recognized as diabetic vascular complication. AGEs exist intra- and extracellularly and are consistent of proteins, lipids, nucleic acids with complicated structures generate protein fluorescence and cross-linking [22]. AGEs accumulate on proteins especially on the large matrix proteins such as collagen, vitronectin, and laminin through AGE-AGE intermolecular covalent bonds in the extracellular matrix (ECM). These bonds increase stiffness of vasculature. RAGE are activated by AGEs and upregulate NF- $\kappa$ B that promote expression of inflammatory cytokines [23]. Proteins with three aromatic amino acids— phenylalanine, tyrosine, and tryptophan display useful intrinsic fluorescence affecting valuable effect to local microenvironment [24].

AGEs promote oxidative stress, expression of inflammatory cytokines and inflammation. These pathological stimuli may cause dynapenia and sarcopenia [25].

Accumulation of AGEs and increased cross-linking of collagen have been observed in elderly, resulting in increased muscle stiffness, reduced muscle function [26]. Cross-linking of collagen can be formed by combining with an amino acid having two aldehyde groups composing of difunctional, trifunctional, and tetrafunctional cross-linking structure. Type I collagen is the most abundant fibrillar type collagen in the body playing important role in fibrosis of bone, skin, and connective tissue [27, 28]. Collagen molecule becomes natural collagen polymer [29]. Skeletal muscle is consistent of muscular cells, and connective tissues including tendon, intramuscular connective tissues, ligament and fascia that are associate with muscle amount and strength. Cross-linking of collagen cause sarcopenia (increased muscle stiffness, reduced muscle function) and weakening of tissues with type I collagen such as bone and skin.

The RAGE plays an important role in ALS causing inflammation oxidative stress and cellular dysfunction. RAGE is also expressed in neurons, vascular cells, microglia, and astrocytes in CNS [30].

### **1.3. Oxidative Stress and Preneoplastic Lesions**

Oxidation is associated with molecular signal pathways for normal physiological processes [31]. Oxidative stress is overproduction and accumulation of reactive oxygen species (ROS) in cells and tissues, and damage cells and tissue. In equilibrium state ROS works to detoxify these reactive products like in the case of bactericidal activity of white blood cells [32]. Superoxide radical is a state in which one extra electron is incorporated into a normal oxygen molecule which is unstable and highly reactive leading to cell and tissue damage. ROS is defined as radicals with unpaired electrons in outer orbitals and potent active chemically [33] including superoxide radicals ( $O_2^{\bullet-}$ ), hydrogen peroxide ( $H_2O_2$ ), hydroxyl radicals ( $\bullet OH$ ), and singlet oxygen ( $^1O_2$ ). Although most of ROS are produced as by-product of oxygen metabolism, ROS is also produced by environmental factors such as ultraviolet (UV) radiation, pollutants (cigarette

smoking, heavy metals) and xenobiotics [34, 35]. Oxidative stress plays an important role in coexistence of various microbes by the production of a variety of protective enzymes leading to reduce the pathogenic biofilm [36]. There are a variety of intracellular producing factors of ROS such as nicotinamide adenine dinucleotide phosphate (NADPH) LPS oxidase (NOX), mitochondrial electron transport chain leakage, and cytokine receptors. ROS play major roles in initiation and progression of a variety of diseases such as cancer, diabetes mellitus (DM), metabolic disorders, atherosclerosis, and cardiovascular diseases [37, 38].

In human gingival fibroblast study, *F. nucleatum* inhibits fibroblast proliferation, promotes cell apoptosis, and produces ROS, and inflammatory cytokine partly through AKT/MAPK and NF- $\kappa$ B signaling pathways [39].

It remains unclarified that *F. nucleatum* induces preneoplastic conditions and contribute to ALS and carcinogenesis. However, *F. nucleatum* resides in tissues of gastric cancer and adjacent mucosa and the prognosis of patients with Lauren's diffuse type gastric cancer with *F. nucleatum*-positive is significantly worse [40]. Diffuse type gastric cancer originates from atrophic gastritis and intestinal metaplasia caused by chronic active inflammation. Long-term chronic *H. pylori*-induced gastric inflammation develops 80% of *H. pylori* positive atrophic gastritis compared with 10% of *H. pylori*-negative gastritis [41]. High *Fusobacteria* abundance in the gastrointestinal tract is associated with microbial translocation in spinal-onset ALS, and also, high oral *Fusobacteria* abundance is correlated with bulbar-onset ALS [42]. Cyclooxygenase-2 (COX-2) is demonstrated to induce imbalance between cell proliferation and apoptosis and detected in ALS, *H. pylori*-positive gastritis, and preneoplastic cancerous lesions [43].

#### 1.4. Oxidative Stress and Metalloproteinases

The activity of gut microbiota is regulated by balance of beneficial and harmful microorganism (symbiosis and dysbiosis) [44]. ROS play a harmful role in excess expression [45]. Oxidative stress, elevated intracellular levels of ROS, are released from phagocytic cells such as macrophages, granulocytes, and dendritic cells and play an important role in inflammation and cancers. ROS have adverse effects on DNA causing acute and chronic inflammation resulting in immunological diseases and neoplasm [46, 47]. It is reported that oxidative stress may be an early activator of MMPs in ischemia-reperfusion experiment. Particularly, MMP-9 plays an important role after ischemic stroke to reestablish blood-brain barrier injury and hemorrhagic transformation [48]. HT is the peripheral blood extravasation through a disrupted blood brain barrier into the brain after acute ischemic stroke [49].

#### 1.5. Neuron and Metalloproteinases

Patients with ALS are vulnerable to most motor neurons, however some neurons such as innervating extraocular, pelvic sphincter and slow limb muscles are resistant. Alpha motor neuron (MN) degenerated by ALS is classified into

three types of motor units, FF (fast-twitch fatigable), FR (fast-twitch fatigue-resistant), and S (slow-twitch fatigue-resistant) [50]. In ALS, degeneration occurs in the order of FF and FR as the condition progresses, and S is known to be resistant to degeneration. Osteopontin (OPN), also called cytokine Eta-1 is synthesized in a variety of tissues and cells. OPN has a variety of roles including bone resorption, immune cell activation, and ECM remodeling [51].

MMP-9 is expressed in fast motor neurons such as spinal cord, brainstem, and cortex that makes the functions selectively vulnerable. Expressing in fast motor neurons, MMP-9 makes selectively vulnerable to them [52]. Transcription factors play important roles in the regulations of osteopontin and MMP-9 (OPN/MMP-9) expression. The activation of MMP-9 is regulated by NF- $\kappa$ B, which is the therapeutic target in patients with ALS [53]. ECM is degraded synergistically with COX-2 and MMP-9, which might be therapeutic target for COX-2 inhibitor celecoxib with the suppressive activity of activated NF- $\kappa$ B [54]. Neurodegeneration is not only caused by OPN/MMP-9, but also by glial and lymphoid cells in the microenvironment, as it were non-cell autonomous neurodegeneration. Various damages stimulate microglia to release a variety of ROS and proinflammatory cytokines, resulting in dysfunction and death of neurons [55]. There exists a close relationship between immune response and oxidative stress, and elevated and dysregulated ROS production from disease-associated microglia causes neurodegenerative diseases [56]. Activated microglia releases proinflammatory cytokines including IL-1, IL-6, and TNF- $\alpha$ . These factors prevent and promote further inflammatory damage in CNS. Chronic activated macrophage contributes neurodegenerative diseases [57].

#### 1.6. CNS and NF- $\kappa$ B

The NF- $\kappa$ B pathway plays a critical role in immune responses through inflammatory cytokines and could be a novel therapeutic target for ALS [58]. The NF- $\kappa$ B proteins reside in the cytoplasm and regulated by inhibitory proteins such as I $\kappa$ B family members and related proteins with ankyrin repeats, which mediate protein-protein interaction with unique motif [59]. I $\kappa$ B $\alpha$  plays a potent inhibitory role, and p50, p52, p100 and p105 are associated with NF- $\kappa$ B inhibition like I $\kappa$ B. C-terminal portion of these proteins is characterized by the structural resemblance of I $\kappa$ B [59, 60].

NF- $\kappa$ B possess two signal pathways, canonical and noncanonical pathways, both of which are independent and have diverse pathophysiological functions.

The canonical pathway responds to various stimuli leading to I $\kappa$ B degradation by ubiquitin-proteasome system (UPS), which induce nuclear translocation p50/RelA rapidly and transiently [61].

The non-canonical NF- $\kappa$ B pathway activates the RelB/p52 through NF- $\kappa$ B-inducing kinase (NIK). The function of this pathway is slow, persistent and specific and responds to TNF receptor (TNFR) signals. NIK play a key role in the stabilization of the pathway, and deregulated NIK accumulation leads to lymphoid malignancies [62].

Astrocytes and microglia produce the cytokines in the immune systems of CNS [63]. Neuroinflammation is associated with the main neurodegeneration of ALS, which is regulated by NF- $\kappa$ B in spinal cords, which causes extensive astrogliosis, activates microglia, and infiltration of peripheral immune cells leading to neurodegeneration 2 [64].

The first line chemotherapy of *H. pylori* is triple therapy with two antibiotics and a proton-pump inhibitor. However, it is reported that *H. pylori* disappears gradually with the change of human gut microbiota [78, 79].

Although the effect of valproic acid (VPA) has not been determined, there are reports that significant prolongation of life with patients with ALS has been shown, and can be used for a long period of time with good tolerance and safety. However, there are some questions on the evaluation. It will be important to bring out the effect of histone deacetylase (HDAC) inhibitors in combination with thalidomide and celecoxib [85-87].

Monoclonal antibodies act on receptors outside of the cells. However, no growing body of evidence supports that the signal reach transcriptional factors that suppress activated NF- $\kappa$ B [88].

Figure	Receptor	signal transduction	transcriptional factor	chromatin	molecular target	ref
Thalidomide			NF-Kb		* $\alpha$ -syn	89
Celecoxib			NF- $\kappa$ B COX-2		COX-2	90
Valproic acid				HDACs		85
* $\alpha$ -synuclein						

Neuroinflammation, activated in glial cells, lead to neurodegeneration in ALS.

Short-chain fatty acids (SCFAs) (e.g., acetate, propionate, butyrate) with anti-inflammatory activity is produced in colon from the fermentation of indigestible fiber. Butyrate plays a potential role in the progression and therapeutic reagent of ALS [91-93].

#### 4.1. Probiotics

Beneficial gut microbiota such as Bifidobacterium and Lactobacillus acidophilus promote immune responses mainly through metabolites including SCFAs, flavonoids and glucosinolates (isothiocyanates) 44 [94]. SCFAs are the main metabolites of dietary fibers and resistant starch in the colon [95].

*F. nucleatum* expresses ROS, RNS and LPS, sequently next, proinflammatory cytokines are released 44. *F. nucleatum* is able to form biofilms to protect from surrounding microenvironment, increasing the formation of biofilm in response to alkaline pH [96, 97].

The pH of atrophic gastritis is generally higher than pH  $\geq 3$  67 [98].

#### 4.2. Berberine

Berberine is derived from *Phellodendron amurense*. It is used in the management of diarrhea and is nontoxic in human normal cells. Berberine is anti-inflammatory agent [99-101]. Berberine down-regulates the cytokines expression. The protein quality control (PQC) system regulates proteostasis through protein folding and degradation. Androgen receptor with elongated polyglutamine (polyQ) tract (ARpolyQ) is a mediator for neuromuscular degeneration in spinal and bulbar muscular atrophy (SBMA) caused by SOD1 [102-104]. Berberine clear the misfolded proteins SOD1 responsible for ALS and might be the therapeutic tool [105-107].

#### 4.3. Thalidomide and Celecoxib

Thalidomide is prescribed an immunomodulatory drug. It is used as mRNA encoding inhibitor such as VEGF and TNF- $\alpha$ . Pro-inflammatory cytokines expression is inhibited by Thalidomide through modulating activated or irregular NF- $\kappa$ B within the CNS [108].

COX-2 is constitutively overexpressed in chronic inflammatory pathogenic mediator in ALS. COX-2, upregulated in spinal astrocytes and neurons, catalyzes PGE<sub>2</sub>, by which stimulates glutamate expression. COX-2, upregulated in spinal astrocytes and neurons, catalyzes PGE<sub>2</sub>, by which stimulates glutamate expression 82 [109]. COX-2 inhibitor celecoxib suppresses the expression of pro-inflammatory cytokines, ROS and active radicals. Symptoms of ALS such as neuromuscular weakness and weight loss could be decreased and prolong survival [84].

#### 4.4. Valproic Acid (VPA)

VPA is prescribed in the treatment of convulsion. Nowadays, it is being used in the management of ALS [110].

It works as HDAC inhibitor and sometimes VPA and immunomodulatory drugs are used to treat ALS.

Long usage of VPA exerts neuroprotective effects with epigenetic alterations in a variety of intracellular signaling pathways [85].

## 5. Conclusion

### 5.1. For Mild ALS

Management and Prevention of ALS is to inhibit pathogens binding to Toll-like receptor 4, and to choose the drugs that works on transcriptional factors such as NF- $\kappa$ B [111].

1. Probiotics + berberine (100-300mg/day p.o) every day
2. Celecoxib (400mg/day) + Valproic acid (600mg/day) every day

### 5.2. For Moderate ALS

1. Probiotics + berberine (100-300mg/day p.o) every day
2. Celecoxib (400mg/day) + Valproic acid (600mg/day) every day
3. Thalidomide (50-100mg/day) every day

### 5.3. For Severe ALS

1. Probiotics + berberine (100-300mg/day p.o) every day
2. Celecoxib (400mg/day) + Valproic acid (600mg/day) every day
3. Thalidomide (200mg/day) every day

There are many side effects in thalidomide use such as birth defects and peripheral neuropathy. It is important to use thalidomide from low dose and not to use it who will be pregnant couple.

## References

- [1] Younus H. Therapeutic potentials of superoxide dismutase. *Int J Health Sci (Qassim)*. 2018; 12 (3): 88-93.
- [2] Frakes AE, Ferraiuolo L, Haidet-Phillips AM. Microglia induce motor neuron death via the classical NF- $\kappa$ B pathway in amyotrophic lateral sclerosis. *Neuron*. 2014; 81 (5): 1009-1023.
- [3] Redler RL, Dokholyan NV. The complex molecular biology of amyotrophic lateral sclerosis (ALS). *Prog Mol Biol Transl Sci*. 2012; 107: 215-262.
- [4] Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. *Lancet Neurol*. 2011 Mar; 10 (3): 253-63.
- [5] Small CD, Crawford BD. Matrix metalloproteinases in neural development: a phylogenetically diverse perspective. *Neural Regen Res*. 2016 Mar; 11 (3): 357-62.
- [6] Łukasiewicz-Zajac M, Mroczko B, Słowik A. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS). *J Neural Transm (Vienna)*. 2014 Nov; 121 (11): 1387-97.

- [7] Pinet K, McLaughlin KA. Mechanisms of physiological tissue remodeling in animals: Manipulating tissue, organ, and organism morphology. *Dev Biol.* 2019 Jul 15; 451 (2): 134-145.
- [8] Singh D, Srivastava SK, Chaudhuri TK. Multifaceted role of matrix metalloproteinases (MMPs). *Front Mol Biosci.* 2015 May 13; 2: 19.
- [9] Yabluchanskiy A, Ma Y, Iyer RP, Hall ME. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. *Physiology (Bethesda).* 2013 Nov; 28 (6): 391-403.
- [10] Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. *Prog Mol Biol Transl Sci.* 2017; 147: 1-73.
- [11] Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. *Trends Cell Biol.* 2001 Nov; 11 (11): S37-43.
- [12] Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. *J Cell Sci.* 2002 Oct 1; 115 (Pt 19): 3719-27.
- [13] Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res.* 2003 May 2; 92 (8): 827-39.
- [14] Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. *Biochim Biophys Acta.* 2010 Jan; 1803 (1): 55-71.
- [15] Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. *Pharmacol Ther.* 2013 Jul; 139 (1): 32-40.
- [16] Jorge Luis Sánchez-Torres, Petra Yescas-Gómez, Julio Torres-Romero, et al, Matrix metalloproteinases deregulation in amyotrophic lateral sclerosis, *Journal of the Neurological Sciences*, Vol. 419, 2020, 117175.
- [17] Wang T, Jin X, Liao Y. Association of NF- $\kappa$ B and AP-1 with MMP-9 Overexpression in 2-Chloroethanol Exposed Rat Astrocytes. *Cells.* 2018; 7 (8): 96.
- [18] Picca A, Fanelli F, Calvani R, Mulè G, Pesce V, Sisto A, Pantanelli C, Bernabei R, Landi F, Marzetti E. Gut Dysbiosis and Muscle Aging: Searching for Novel Targets against Sarcopenia. *Mediators Inflamm.* 2018 Jan 30; 2018: 7026198.
- [19] Dhillon RJ, Hasni S. Pathogenesis and Management of Sarcopenia. *Clin Geriatr Med.* 2017; 33 (1): 17-26.
- [20] DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care.* 2009 Nov; 32 Suppl 2 (Suppl 2): S157-63.
- [21] Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. *Diabetologia.* 2001 Feb; 44 (2): 129-46.
- [22] Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. *Diabetes Res Clin Pract.* 2005 Jan; 67 (1): 3-21.
- [23] Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation.* 2006 Aug 8; 114 (6): 597-605.
- [24] In: Lakowicz J. R. (eds) (2006) *Protein Fluorescence. Principles of Fluorescence Spectroscopy.* Springer, Boston, MA. 45-50.
- [25] Mori H, Kuroda A, Ishizu M. Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes. *J Diabetes Investig.* 2019 Sep; 10 (5): 1332-1340.
- [26] Sun K, Semba RD, Fried LP, Schaumburg DA, Ferrucci L, Varadhan R. Elevated Serum Carboxymethyl-Lysine, an Advanced Glycation End Product, Predicts Severe Walking Disability in Older Women: The Women's Health and Aging Study I. *J Aging Res.* 2012; 2012: 586385.
- [27] Snedeker JG, Gautieri A. The role of collagen crosslinks in ageing and diabetes - the good, the bad, and the ugly. *Muscles Ligaments Tendons J.* 2014; 4 (3): 303-308.
- [28] Gordon MK, Hahn RA. Collagens. *Cell Tissue Res.* 2010; 339 (1): 247-257.
- [29] Tanzer ML. Cross-linking of collagen. *Science.* 1973 May 11; 180 (4086): 561-6.
- [30] Juranek JK, Daffu GK, Wojtkiewicz J. Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis. *Front Cell Neurosci.* 2015; 9: 485.
- [31] Auten RL, Davis JM. Oxygen toxicity and reactive oxygen species: the devil is in the details. *Pediatr Res.* 2009 Aug; 66 (2): 121-7.
- [32] Pizzino G, Irrera N, Cucinotta M, Oxidative Stress: Harms and Benefits for Human Health. *Oxid Med Cell Longev.* 2017; 2017: 8416763.
- [33] Southorn PA, Powis G. Free radicals in medicine. I. Chemical nature and biologic reactions. *Mayo Clin Proc.* 1988 Apr; 63 (4): 381-9.
- [34] Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. *Physiol Rev.* 2014; 94 (2): 329-354.
- [35] Atashgahi S, Shetty SA, Smidt H, de Vos WM. Flux, Impact, and Fate of Halogenated Xenobiotic Compounds in the Gut. *Front Physiol.* 2018 Jul 10; 9: 888.
- [36] Marquis RE. Oxygen metabolism, oxidative stress and acid-base physiology of dental plaque biofilms. *J Ind Microbiol.* 1995 Sep; 15 (3): 198-207.
- [37] Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. *Hypertension.* 2003 Dec; 42 (6): 1075-81.
- [38] Rojas F, Gonzalez D, Cortes N. Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling. *Front Cell Neurosci.* 2015 Jun 9; 9: 203.
- [39] Kang W, Jia Z, Tang D. *Fusobacterium nucleatum* Facilitates Apoptosis, ROS Generation, and Inflammatory Cytokine Production by Activating AKT/MAPK and NF- $\kappa$ B Signaling Pathways in Human Gingival Fibroblasts. *Oxid Med Cell Longev.* 2019 Oct 13; 2019: 1681972.
- [40] Boehm E. T., Thon C., Kupcinkas J. *Fusobacterium nucleatum* is associated with worse prognosis in Lauren's diffuse type gastric cancer patients. *Sci Rep* 10, 16240 (2020).

- [41] Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer. *Oncol Lett*. 2016 May; 11 (5): 2959-2964.
- [42] Kim, H. S., Son, J., Lee, D. Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset. *BMC Neurol* 1023; 22, 62: 45-50.
- [43] Nardone G, Rocco A, Malfertheiner P. Review article: helicobacter pylori and molecular events in precancerous gastric lesions. *Aliment Pharmacol Ther*. 2004 Aug 1; 20 (3): 261-70.
- [44] Whisner CM, Athena Aktipis C. The Role of the Microbiome in Cancer Initiation and Progression: How Microbes and Cancer Cells Utilize Excess Energy and Promote One Another's Growth. *Curr Nutr Rep*. 2019 Mar; 8 (1): 42-51.
- [45] Ballard JWO, Towarnicki SG. Mitochondria, the gut microbiome and ROS. *Cell Signal*. 2020 Nov; 75: 109737.
- [46] Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. *Curr Biol*. 2014; 24 (10): R453-R462.
- [47] Mori K, Shibnuma M, Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. *Cancer Res*. 2004 Oct 15; 64 (20): 7464-72.
- [48] Gasche Y, Copin JC, Sugawara T. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. *J Cereb Blood Flow Metab*. 2001 Dec; 21 (12): 1393-400.
- [49] Spronk E, Sykes G, Falcione S. Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. *Front Neurol*. 2021; 12: 66-70.
- [50] Morisaki Y, Niikura M, Watanabe M. back to 50 Selective Expression of Osteopontin in ALS-resistant Motor Neurons is a Critical Determinant of Late Phase Neurodegeneration Mediated by Matrix Metalloproteinase-9. *Sci Rep*. 2016 Jun 6; 6: 27354.
- [51] Singh M, Foster CR, Dalal S. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. *J Mol Cell Cardiol*. 2010 Mar; 48 (3): 538-43.
- [52] Kaplan A, Spiller KJ, Towne C. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. *Neuron*. 2014 Jan 22; 81 (2): 333-48.
- [53] Guarneri C, Bevelacqua V, Polesel J. NF- $\kappa$ B inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma. *Oncol Rep*. 2017 Feb; 37 (2): 737-746.
- [54] Lazăr L, Loghin A, Bud ES. Cyclooxygenase-2 and matrix metalloproteinase-9 expressions correlate with tissue inflammation degree in periodontal disease. *Rom J Morphol Embryol*. 2015; 56 (4): 1441-6.
- [55] Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. *Nagoya J Med Sci*. 2015 Nov; 77 (4): 537-49.
- [56] Simpson DSA, Oliver PL. ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease. *Antioxidants (Basel)*. 2020 Aug 13; 9 (8): 743.
- [57] Smith JA, Das A, Ray SK. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. *Brain Res Bull*. 2012 Jan 4; 87 (1): 10-20.
- [58] Dutta K, Thammisetty SS, Boutej H. Mitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling. *J Neurosci*. 2020 Jun 24; 40 (26): 5137-5154.
- [59] Ting Liu, Lingyun Zhang, Donghyun Joo. NF- $\kappa$ B signaling in inflammation *Signal Transduct Target Ther*. 2017; 2: 17023.
- [60] Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. *Biochem J*. 2004; 382 (Pt 2): 393-409.
- [61] Liu T, Zhang L, Joo D. NF- $\kappa$ B signaling in inflammation. *Signal Transduct Target Ther*. 2017; 2: 17023.
- [62] Sun SC. Non-canonical NF- $\kappa$ B signaling pathway. back to 60 *Cell Res*. 2011; 21 (1): 71-85.
- [63] Källstig E, McCabe BD, Schneider BL. The Links between ALS and NF- $\kappa$ B. *Int J Mol Sci*. 2021 Apr 8; 22 (8): 3875.
- [64] Dresselhaus EC, Meffert MK. Cellular Specificity of NF- $\kappa$ B Function in the Nervous System. *Front Immunol*. 2019 May 9; 10: 1043.
- [65] Zhou Y, Ji X, Chen J, Fu Y, Huang J Short-chain fatty acid butyrate: A novel shield against chronic gastric ulcer. *Exp Ther Med*. 2021 Apr; 21 (4): 329.
- [66] Zhu H, Hart CA, Sales D. Bacterial killing in gastric juice--effect of pH and pepsin on *Escherichia coli* and *Helicobacter pylori*. *J Med Microbiol*. 2006 Sep; 55 (Pt 9): 1265-1270.
- [67] Sung J, Kim N, Lee J. Associations among Gastric Juice pH, Atrophic Gastritis, Intestinal Metaplasia and *Helicobacter pylori* Infection. *Gut Liver*. 2018; 12 (2): 158-164.
- [68] Martinsen TC, Fossmark R, Waldum HL. The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid. *Int J Mol Sci*. 2019; 20 (23): 6031. Published 2019 Nov 29.
- [69] Afroze S, Meng F, Jensen K. The physiological roles of secretin and its receptor. *Ann Transl Med*. 2013; 1 (3): 29.
- [70] Silva, D. F., Candeias, E., Esteves, A. R. Microbial BMAA elicits mitochondrial dysfunction, innate immunity activation, and Alzheimer's disease features in cortical neurons. *J Neuroinflammation* 2020-17, 332-334.
- [71] Okamoto, S., Esumi, S., Hamaguchi-Hamada, K.  $\beta$ -N-methylamino-L-alanine (BMAA) suppresses cell cycle progression of non-neuronal cells. *Sci Rep* 2018; 8: 17-20.
- [72] Banack SA, Caller TA, Stommel EW. The cyanobacteria derived toxin Beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis. *Toxins (Basel)*. 2010; 2 (12): 2837-2850.
- [73] Nunes-Costa D, Magalhães JD, G-Fernandes M. Microbial BMAA and the Pathway for Parkinson's Disease Neurodegeneration. *Front Aging Neurosci*. 2020; 12: 26.
- [74] Vega AE, Cortiñas TI, Mattana CM. Growth of *Helicobacter pylori* in medium supplemented with cyanobacterial extract. *J Clin Microbiol*. 2003 Dec; 41 (12): 5384-8.
- [75] Thomas RM, Jobin C. The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real? *Trends Cancer*. 2015; 1 (1): 24-35.
- [76] Gorlé N, Bauwens E, Haesebrouck F. *Helicobacter* and the Potential Role in Neurological Disorders: There Is More Than *Helicobacter pylori*. *Front Immunol*. 2021; 11: 58-60. 4165.

- [77] Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: Married by the laws of inflammation. *World J Gastrointest Pathophysiol.* 2014; 5 (4): 400-404.
- [78] Saxena A, Mukhopadhyay AK, Nandi SP. Helicobacter pylori: Perturbation and restoration of gut microbiome. *J Biosci.* 2020; 45 (1): 110.
- [79] Vale FF, Oleastro M. Overview of the phytomedicine approaches against Helicobacter pylori. *World J Gastroenterol.* 2014; 20 (19): 5594-609.
- [80] Belov Kirdajova D, Kriska J, Tureckova J. Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells. *Front Cell Neurosci.* 2020 Mar 19; 14: 51.
- [81] Wang JP, Kurt-Jones EA, Shin OS. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. *J Virol.* 2005; 79 (20): 12658-12666.
- [82] Pandya RS, Zhu H, Li W. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. *Cell Mol Life Sci.* 2013 Dec; 70 (24): 4729-45.
- [83] Xia, Q., Hu, Q., Wang, H. Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. *Cell Death Dis.* 2015; 11: 17-19.
- [84] Drachman DB, Frank K, Dykes-Hoberg M. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. *Ann Neurol.* 2002 Dec; 52 (6): 771-8.
- [85] Sugai F, Yamamoto Y, Miyaguchi K, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. *Eur J Neurosci.* 2004 Dec; 20 (11): 3179-83.
- [86] Piepers S, Veldink JH, de Jong SW. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. *Ann Neurol.* 2009 Aug; 66 (2): 227-34.
- [87] Coppede F. Targeting the epigenome to treat neurodegenerative diseases or delay their onset: a perspective. *Neural Regen Res.* 2022 Aug; 17 (8): 1745-1747.
- [88] Sibertin-Blanc C, Ciccolini J, Norguet E. Monoclonal antibodies for treating gastric cancer: promises and pitfalls. *Expert Opin Biol Ther.* 2016 Jun; 16 (6): 759-69.
- [89] Valera E, Mante M, Anderson S. Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. *J Neuroinflammation.* 2015 May 14; 12: 93.
- [90] Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. *Cell.* 2010 Mar 19; 140 (6): 918-34.
- [91] Nicholson K, Bjornevik K, Abu-Ali G, et al. The human gut microbiota in people with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener.* 2021 May; 22 (3-4): 186-194.
- [92] Zhang YG, Wu S, Yi J. Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. *Clin Ther.* 2017; 39 (2): 322-336.
- [93] Geller LT, Barzily-Rokni M, Danino T. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science.* 2017 Sep 15; 357 (6356): 1156-1160.
- [94] Coutzac, C., Jouniaux, JM., Paci, A. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. *Nat Commun* 11, 2168 (2020).
- [95] Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. *Front Endocrinol (Lausanne).* 2020; 11: 25.
- [96] Chew J, Zilm PS, Fuss JM, et al. A proteomic investigation of Fusobacterium nucleatum alkaline-induced biofilms. *BMC Microbiol.* 2012 Sep 3; 12: 189.
- [97] Jones EM, Cochrane CA, Percival SL. The Effect of pH on the Extracellular Matrix and Biofilms. *Adv Wound Care (New Rochelle).* 2015; 4 (7): 431-439.
- [98] O'May GA, Reynolds N, Smith AR. Effect of pH and antibiotics on microbial overgrowth in the stomachs and duodena of patients undergoing percutaneous endoscopic gastrostomy feeding. *J Clin Microbiol.* 2005; 43 (7): 3059-3065.
- [99] Zou K, Li Z1, Zhang Y, et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. *Acta Pharmacol Sin.* 2017 Feb; 38 (2): 157-167.
- [100] Wang H, Zhu C, Ying Y. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. *Oncotarget.* 2017 Sep 11; 9 (11): 10135-10146.
- [101] QiangZhanga, XiaobingWangb, ShijieCaoc. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. *Biomedicine & Pharmacotherapy* 2020; 128: 115-120.
- [102] Rusmini P, Cristofani R, Tedesco B, et al. Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives. *Int J Mol Sci.* 2020 May 13; 21 (10): 3443.
- [103] Cicardi ME, Cristofani R, Crippa V. Autophagic and Proteasomal Mediated Removal of Mutant Androgen Receptor in Muscle Models of Spinal and Bulbar Muscular Atrophy. *Front Endocrinol (Lausanne).* 2019 Aug 20; 10: 569.
- [104] Giorgetti E, Lieberman AP. Polyglutamine androgen receptor-mediated neuromuscular disease. *Cell Mol Life Sci.* 2016 Nov; 73 (21): 3991-9.
- [105] Lin JP, Yang JS, Wu CC, et al. Berberine induced down-regulation of matrix metalloproteinase-1, -2 and -9 in human gastric cancer cells (SNU-5) in vitro. *In Vivo.* 2008 Mar-Apr; 22 (2): 223-30.
- [106] Münch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. *Proc Natl Acad Sci U S A.* 2011 Mar 1; 108 (9): 3548-53.
- [107] Kim HJ, Yim GW, Nam EJ, et al. Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3. *Cancer Res Treat.* 2014 Jan; 46 (1): 81-92.
- [108] Jung YJ, Tweedie D, Scerba MT, et al. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. *Front Cell Dev Biol.* 2019 Dec 4; 7: 313.



- [109] Yasojima K, Tourtellotte WW, McGeer EG. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. *Neurology*. 2001; 57 (6): 952-6.
- [110] Fushida S, Kinoshita J, Kaji M, et al Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial. *Drug Des Devel Ther*. 2016 Jul 25; 10: 2353-8.
- [111] Lee JY, Lee JD, Phipps S. Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. *J Neuroinflammation*. 2015; 12: 90.